



**Novartis India Limited**  
Registered Office:  
Inspire BKC  
Part of 601 & 701  
Bandra Kurla Complex  
Bandra (East)  
Mumbai – 400 051  
Maharashtra, India  
Tel +91 22 50243000  
Fax +91 22 50243010  
Email: india.investors@novartis.com  
CIN No. L24200MH1947PLC006104  
Website: www.novartis.in

November 09, 2022

The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Scrip Code: 500672

Dear Sir/ Madam,

**Sub.: Outcome of the Meeting of the Board of Directors of Novartis India Limited ('the Company') held today i.e. Wednesday, November 09, 2022**

In continuation to our letter dated September 30, 2022 and pursuant to Regulations 30 (read with Para A of Part A of Schedule III) and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('**SEBI Listing Regulations**') read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 ('**SEBI Circular**'), wherever applicable, we hereby inform that the Board of Directors of the Company at its Meeting held today i.e. November 09, 2022 have, *inter-alia*, approved the following matters:

**1. Unaudited Financial Results:**

The Board of Directors of the Company, as recommended by the Audit Committee, have considered and approved the Unaudited Financial Results of the Company for the quarter ended September 30, 2022.

In terms of Regulation 33 of SEBI Listing Regulations, please find enclosed below as '**Annexure I**':

- a) the Unaudited Financial Results along with for the quarter and half year ended September 30, 2022; and
- b) Limited Review Report dated November 09, 2022, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and taken on record by the Board of the Company.

**2. Appointment of Ms. Shilpa Joshi (DIN: 09775615) as Additional Director (designated as 'Whole-Time Director and Chief Financial Officer') of the Company:**

Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Ms. Shilpa Joshi (DIN: 09775615) as:

- a) Additional Director of the Company with effect from November 22, 2022; and
- b) Whole-Time Director (designated as 'Whole-Time Director and Chief Financial Officer') of the Company for a period of 5 (five) years with effect from November 22, 2022 upto November 21, 2027 subject to the approval of the Members of the Company

The Company shall seek approval of the Members of the Company in due course and within the prescribed timelines, in accordance with the SEBI Listing Regulations, wherever required.



Ms. Shilpa Joshi is not debarred from holding the office of Director by virtue of any SEBI order or any other such Authority.

The details as required under SEBI Circular along with her brief profile is given in 'Annexure II' to this letter.

**3. Resignation of Ms. Monaz Noble (DIN: 03086192) as Director:**

Ms. Monaz Noble (DIN: 03086192) resigned from her position of Non-Executive and Non-Independent Director of the Company with effect from the close of business hours of November 21, 2022.

The details as required under SEBI Circular is given in 'Annexure III' to this letter.

The said Meeting commenced at 2.00 p.m. and concluded at 4.35 p.m.

The above is for your information and the same is also available on the Company's website i.e. [www.novartis.in](http://www.novartis.in)

Thanking you

Yours Sincerely,

For **Novartis India Limited**



**Nikhil Malpani**  
**Company Secretary and Compliance Officer**



**Malpani**  
**Nikhil**

Digitally signed by Malpani Nikhil  
DN: dc=com, dc=novartis,  
ou=people, ou=GR,  
serialNumber=3079258, cn=Malpani  
Nikhil  
Date: 2022.11.09 16:53:11 +05'30'

Novartis India Limited							
Regd. off: Inspire - BKC, Part of 601 and 701, Bandra Kurla Complex, Bandra East, Mumbai 400051							
www.novartis.in, CIN: L24200MH1947PLC006104							
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30.09.2022 (₹ in millions)							
Sr. No.	Particulars	3 months ended	3 months ended	3 months ended	6 months ended	6 months ended	Year ended
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1.	Revenue from Operations	1,015.2	1,209.2	1,044.8	2,224.4	2,025.9	3,996.7
	Other Income [Refer note 4]	68.6	265.2	63.8	333.8	128.4	331.9
	<b>Total Income</b>	<b>1,083.8</b>	<b>1,474.4</b>	<b>1,108.6</b>	<b>2,558.2</b>	<b>2,154.3</b>	<b>4,330.6</b>
2.	Expenses						
	(a) Purchases of Stock-in-Trade	524.5	428.5	372.2	953.0	824.5	1,872.6
	(b) Changes in Inventories of Stock-in-Trade	(14.2)	146.0	78.4	131.8	25.3	(91.3)
	(c) Employee Benefits Expense	115.1	91.6	271.6	206.7	552.9	1,018.9
	(d) Finance Costs	4.9	5.0	15.0	9.9	30.4	48.3
	(e) Depreciation and Amortisation Expense	13.8	13.0	26.8	26.8	55.9	96.5
	(f) Other Expenses	226.6	225.1	251.7	451.7	473.9	927.4
	<b>Total Expenses</b>	<b>870.7</b>	<b>909.2</b>	<b>1,015.7</b>	<b>1,779.9</b>	<b>1,962.9</b>	<b>3,872.4</b>
3.	Profit before exceptional items and tax	213.1	565.2	92.9	778.3	191.4	458.2
4.	Exceptional item (Refer Note 5)	-	-	-	-	-	495.4
5.	Profit/(Loss) before tax	213.1	565.2	92.9	778.3	191.4	(38.2)
6.	Tax Expense						
	Current Tax	88.8	90.0	29.3	178.8	71.1	-
	Deferred Tax	(21.7)	57.0	(6.6)	35.3	(12.7)	3.4
	Tax adjustment for earlier years	(37.5)	(105.6)	-	(143.1)	-	(4.4)
	<b>Total Tax Expense</b>	<b>29.6</b>	<b>41.4</b>	<b>22.7</b>	<b>71.0</b>	<b>58.4</b>	<b>(1.0)</b>
7.	Profit/(Loss) for the period / year	183.5	523.8	70.2	707.3	133.0	(37.2)
8.	Other Comprehensive Income						
	- Items that will not be reclassified to profit or loss	-	-	61.1	-	61.1	81.9
	Remeasurements of the defined benefit plans	-	-	81.7	-	81.7	109.5
	Income tax relating to these items	-	-	(20.6)	-	(20.6)	(27.6)
9.	Total Comprehensive Income/(loss) for the period / year	183.5	523.8	131.3	707.3	194.1	44.7
10.	Paid-up Equity Share Capital (Face Value ₹ 5 each)	123.4	123.4	123.4	123.4	123.4	123.4
11.	Other Equity						6,793.6
12.	Earnings Per Share (in ₹) (Basic & Diluted)- (of ₹ 5 each) (*not annualised)	7.43 *	21.21 *	2.84 *	28.64 *	5.39 *	(1.51)

## Notes:

## 1. Statement of Assets and Liabilities

Particulars	(₹ in millions)	
	As at 30.09.2022 (Unaudited)	As at 31.03.2022 (Audited)
<b>A Assets</b>		
<b>Non-Current Assets</b>		
Property, Plant and Equipment	29.5	34.8
Right-of-Use Assets	179.8	201.7
Financial Assets		
(i) Loans	-	5.8
(ii) Other Financial Assets	30.8	35.9
Deferred Tax Assets	236.4	271.8
Income Tax Assets (Net)	1,703.0	1,583.8
Other Non-Current Assets	296.8	354.6
	<b>2,476.3</b>	<b>2,488.4</b>
Assets held for sale	9.5	9.1
<b>Current Assets</b>		
Inventories	438.9	570.7
Financial Assets		
(i) Trade Receivables	553.8	445.6
(ii) Cash and Cash Equivalents	76.2	1,583.5
(iii) Bank Balances other than (ii) above	5,575.2	3,592.8
(iv) Loans	5.0	4.6
(v) Other Financial Assets	100.3	119.8
Other Current Assets	744.4	761.2
	<b>7,493.8</b>	<b>7,078.2</b>
<b>TOTAL ASSETS</b>	<b>9,979.6</b>	<b>9,575.7</b>
<b>B Equity and Liabilities</b>		
<b>Equity</b>		
Equity Share Capital	123.4	123.4
Other Equity	7,263.8	6,793.6
	<b>7,387.2</b>	<b>6,917.0</b>
<b>Liabilities</b>		
<b>Non-Current Liabilities</b>		
Financial Liabilities		
(i) Lease Liabilities	184.7	182.7
(ii) Other Financial Liabilities	87.6	13.3
Provisions	282.7	298.5
	<b>555.0</b>	<b>494.5</b>
<b>Current Liabilities</b>		
Financial Liabilities		
(i) Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	1.9	17.5
- total outstanding dues of creditors other than micro enterprises and small enterprises	559.5	704.5
(ii) Lease Liabilities	35.2	57.4
(iii) Other Financial Liabilities	537.4	301.3
Other Current Liabilities	42.9	94.7
Provisions	711.0	906.2
Current Tax Liabilities (Net)	149.5	82.6
	<b>2,037.4</b>	<b>2,164.2</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>9,979.6</b>	<b>9,575.7</b>



## 2 Statement of Cash Flows:

(₹ in millions)

Particulars	Six months ended 30.09.2022 (Unaudited)	Six months ended 30.09.2021 (Unaudited)
<b>A. Cash flow from operating activities</b>		
Profit/(Loss) before tax	778.3	191.4
<b>Adjustments for -</b>		
Depreciation and Amortisation Expense	26.8	55.9
Share Based Payments	2.7	10.1
Interest Income	(328.2)	(78.4)
Unwinding of discount on security deposits	(0.7)	(1.3)
Finance Costs	9.9	30.4
Loss / (Gain) on sale of Property, Plant and Equipment (Net)	(1.7)	1.0
Unrealised Gain on Foreign currency translations (Net)	1.6	(0.6)
Credit Balances Written-Back	(1.5)	(0.8)
Provision for credit Impaired debt, Advances and Deposits	12.3	2.9
<b>Operating cash flows before working capital changes</b>	<b>499.5</b>	<b>210.6</b>
<b>Movement in operating assets and liabilities</b>		
Trade Receivables	(111.0)	15.3
Inventories	131.8	12.3
Financial Assets	57.3	281.2
Other Non-Current Assets	58.4	(3.5)
Other Current Assets	10.5	91.4
Trade Payables	(157.3)	(99.0)
Provisions	(211.1)	21.7
Other Current Liabilities	(51.8)	(84.6)
Financial Liabilities	308.6	19.2
<b>Cash generated from operations</b>	<b>534.9</b>	<b>464.6</b>
Income Tax (Net)	129.1	(87.8)
<b>Net cash generated from operating activities</b>	<b>664.0</b>	<b>376.8</b>
<b>B. Cash flow from investing activities</b>		
Payments for Property, Plant and Equipment	(39.6)	(0.9)
Proceeds from disposal of Property, Plant and Equipment	41.7	(0.8)
Interest received	84.5	92.8
Fixed deposits (net)	(1,980.6)	(23.5)
<b>Net cash (used in)/from investing activities</b>	<b>(1,894.0)</b>	<b>67.6</b>
<b>C. Cash flow from financing activities</b>		
Proceeds from Long-term Borrowings		
Lease payments	(30.1)	(61.0)
Finance cost paid	(0.3)	(0.4)
Dividends paid	(246.3)	(246.7)
<b>Net cash (used in) financing activities</b>	<b>(277.3)</b>	<b>(308.1)</b>
Net (Decrease)/Increase in Cash and Cash Equivalents	<b>(1,507.3)</b>	<b>136.3</b>
Cash and Cash Equivalents - At the beginning of the period	<b>1,583.5</b>	<b>682.7</b>
Cash and Cash Equivalents - At the end of the period	<b>76.2</b>	<b>819.0</b>

- This unaudited financial results for the quarter and six months ended 30 September, 2022 (the 'Statement') has been reviewed by the Audit Committee at its meeting held on 09 November, 2022 and approved at the meeting of the Board of Directors held on that date and has been subjected to limited review by the statutory auditors of the Company.
- This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies, to the extent applicable.
- The Company has a single business segment namely 'Pharmaceuticals Business'.
- Other income includes interest on Income tax refund aggregating to ₹215.6 millions for the quarter ended 30 June, 2022 and six months ended 30 September, 2022.
- The Company had entered into an exclusive sales and distribution agreement with Dr. Reddy's Laboratories Limited of its Established Medicine brands. This strategic business decision has led to an exceptional expense of ₹ 496.4 millions (net of re-evaluation of retirement obligations) for the year ended 31 March, 2022 towards its erstwhile associates under employee separation scheme.

By Order of the Board

Sanjay Murdeshwar  
 Vice Chairman and Managing Director  
 DIN:01481811  
 Mumbai, 09 November, 2022



# B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,  
Nesco IT Park 4, Nesco Center,  
Western Express Highway, Goregaon (East),  
Mumbai - 400 063, India

Telephone: +91 22 6257 1000  
Fax: +91 22 6257 1010

## Limited Review Report on unaudited financial results of Novartis India Limited for the quarter ended 30 September 2022 and year-to-date results for the period from 01 April 2022 to 30 September 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

### To the Board of Directors of Novartis India Limited

1. We have reviewed the accompanying Statement of unaudited financial results of Novartis India Limited ("the Company") for the quarter ended 30 September 2022 and year-to-date results for the period from 01 April 2022 to 30 September 2022 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The financial results for the three months ended 30 June 2022 included in the Statement have been reviewed by the predecessor auditor whose report dated 27 July 2022 had expressed an unmodified conclusion. It has been furnished to us and has been relied upon by us for the purpose of our review of the Statement.  
Our conclusion is not modified in respect of this matter.
6. The financial statements of the Company for the year ended 31 March 2022 have been audited by the predecessor auditor whose report dated 19 May 2022 had expressed an unmodified opinion. The financial information of the Company for the corresponding quarter ended 30 September 2021 and the corresponding period from 01 April 2021 to 30 September 2021 has been reviewed by the predecessor auditor whose report dated 11 November 2021 had expressed an unmodified conclusion.

Registered Office:

B S R & Co. LLP

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022



**Maulik Jhaveri**

*Partner*

Membership No.: 116008

UDIN:22116008BCOMTV5582

Mumbai

09 November 2022

**Appointment of Ms. Shilpa Joshi (DIN: 09775615) as Additional Director (designated as 'Whole-Time Director and Chief Financial Officer') of the Company**

Sr. No.	Particulars	Details
1.	Name of the Director	Ms. Shilpa Joshi (DIN: 09775615)
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of Ms. Shilpa Joshi (DIN: 09775615) as Whole-Time Director (designated as 'Whole-Time Director and Chief Financial Officer') of the Company
3.	Date of appointment/ <del>cessation</del> (as applicable)	With effect from November 22, 2022
4.	Term of Appointment	For a period of 5 (five) years with effect from November 22, 2022 upto November 21, 2027 (liable to retire by rotation)
5.	Brief Profile (in case of appointment)	<p>Ms. Shilpa Joshi is presently working as Chief Financial Officer of the Company with effect from May 01, 2022.</p> <p>Ms. Joshi is Cost and Management Accountant with an extensive and noteworthy career in the healthcare industry spanning over 30 years with an exposure to international and in-country roles. Out of her 30-year remarkable journey, Ms. Joshi has been associated with Novartis for the past 20 years, wherein she has shouldered various roles of increasing responsibilities and impact. In her last role, Ms. Joshi headed the finance and commercial excellence functions for India Oncology. In addition, she was also responsible for leading the commercial operations for Sri-Lanka &amp; Maldives. Ms. Joshi has also played an integral part in providing strategic direction in her brief stint as Franchise Head for Breast Cancer.</p> <p>She is the recipient of several Global &amp; Regional Oncology awards recognizing her efforts and contributions on projects aimed at improving cost efficiencies. Her greatest strengths have been driving simplification of processes through digitization, designing astute insight-driven integrated strategies and bring them alive through robust planning and execution.</p> <p>Prior to joining Novartis, she has worked with Fiat Pvt Ltd, Clariant India Ltd and Wander India Limited.</p>
6.	Disclosure of relationships between directors (in case of appointment of a director)	Ms. Shilpa Joshi is not related <i>inter-se</i> to any Director of the Company



**Resignation of Ms. Monaz Noble (DIN: 03086192) as Director of the Company**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
1.	Name of the Director	Ms. Monaz Noble (DIN: 03086192)
2.	Reason for change viz. <del>appointment,</del> resignation, <del>removal,</del> death or otherwise	Resignation of Ms. Monaz Noble (DIN: 03086192) from the position of Non-Executive and Non- Independent Director of the Company to explore new opportunities to broaden her horizons
3.	Date of <del>appointment/</del> cessation (as applicable)	With effect from close of business hours of November 21, 2022
4.	Term of Appointment	Not Applicable
5.	Brief Profile (in case of appointment)	Not Applicable
6.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

